ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Immunogen (NASDAQ:IMGN) announces its next round of earnings this Friday, February 12. Here is Benzinga's everything-that-matters guide for this Friday's Q4 earnings announcement.

Earnings Preview: Immunogen

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results

ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference

ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference

ImmunoGen: Update On A Turnaround Story

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock?

Why Is ImmunoGen (IMGN) Down 0.5% Since Last Earnings Report?

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia

ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences

ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences

ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.

ImmunoGen (IMGN) Q3 Earnings & Sales Top, Pipeline on Track

ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q3 2020 Results - Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference

ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ImmunoGen (IMGN) Q3 Earnings Expected to Decline

India's Gland Pharma, a majority-owned subsidiary of Shanghai Fosun Pharma, was approved for an $814 million IPO on India's Sebi exchange. Huadong Medicine in-licensed greater China rights to an antibody-drug conjugate developed by ImmunoGen in a $305 million agreement.

Week In Review: Fosun's Gland Pharma Approved For $814 Million IPO In India

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results

ImmunoGen (IMGN) grants exclusive rights to Huadong Medicine for development and commercialization of mirvetuximab soravtansine in Greater China.

ImmunoGen (IMGN) Inks Mirvetuximab Development Deal in China

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility

ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility

The FDA bestows a Breakthrough Therapy status on ImmunoGen's (IMGN) IMGN632 for treating patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Shares rise.

ImmunoGen's Rare Blood Cancer Candidate Gets Breakthrough Tag

ImmunoGen Inc. (NASDAQ: IMGN) shares pushed higher to start out the week when the U.S.

ImmunoGen Sees Solid Win With FDA Update

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C.

News for ImmunoGen Stock (IMGN)